Application of ginsenoside CK and Rh1 and composition thereof in preparation of medicine for improving non-alcoholic fatty hepatic fibrosis and insulin resistance

A technology for fatty liver fibrosis and insulin resistance, which is applied in drug combination, digestive system, pharmaceutical formulation, etc., to achieve the effect of improving the degree of liver fibrosis, improving insulin resistance, and reducing cellular steatosis

Active Publication Date: 2015-11-04
KUNMING NOVOGINSENG BIOENG
View PDF4 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] On the other hand, ginsenoside CK, Rh 1 There is no literature report on the impr

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of ginsenoside CK and Rh1 and composition thereof in preparation of medicine for improving non-alcoholic fatty hepatic fibrosis and insulin resistance
  • Application of ginsenoside CK and Rh1 and composition thereof in preparation of medicine for improving non-alcoholic fatty hepatic fibrosis and insulin resistance
  • Application of ginsenoside CK and Rh1 and composition thereof in preparation of medicine for improving non-alcoholic fatty hepatic fibrosis and insulin resistance

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Embodiment 1: Ginsenoside CK, Rh 1 and CK:Rh 1 In vitro study of =1:1 regulation of gene expression related to collagen synthesis and degradation in rat hepatic stellate cells HSC-T6

[0035] (1) Materials and methods

[0036] 1. Cell line: Rat hepatic stellate cell line HSC-T6 was purchased from the cell bank of Kunming Institute of Zoology, Chinese Academy of Sciences. The phenotype is activated HSC with fibrosis characteristics. HSC-T6 cell lines were incubated with DMEM medium containing 100 U / mL penicillin, 100 μg / mL streptomycin and 10% heat-inactivated fetal calf serum at 37°C with a volume fraction of 5% CO 2 Culture in an incubator, replace the medium after 48 hours, digest with 0.25% trypsin when the cells grow to 80% density, passage once every 2~3 days, and use the logarithmic growth phase cells in the experiment.

[0037] 2. Ginsenoside CK, Rh 1 and CK:Rh 1 =1:1 effect on apoptosis of HSC-T6 cells

[0038] Take HSC-T6 in the logarithmic growth phase, ...

Embodiment 2

[0046] Embodiment 2: Ginsenoside CK, Rh 1 and CK:Rh 1 Effect of =1:1 on nonalcoholic fatty liver fibrosis and insulin resistance in rats

[0047] (1) Materials and methods

[0048] 1. Experimental animals

[0049] Clean-grade healthy male SD rats, 5 weeks old, weighing 160±10g, were provided by the Animal Department of Kunming Medical University, and the animal qualification certificate number: SCXK (Dian) 2005-2008. Raised in separate cages under the condition of no special pathogenic bacteria (SPF), controlled room temperature (23±1oC), humidity 40%, 12 hours in light and dark, free to forage for food and drink water.

[0050] 2. Preparation of main reagents

[0051] High-fat feed: cholesterol (1%) + bile salt (0.3%) + propylthiouracil (0.1%) + lard (10%) + egg yolk (10%) + cornmeal (78.6%); common feed: for The standard feed for experimental animals was prepared by the Animal Department of Kunming Medical University, with an energy density of 14.56 kJ / g.

[0052] 3. M...

Embodiment 3

[0124] Example 3: Ginsenoside CK, Rh 1 and CK:Rh 1 =1:1 preparation of dispersible tablets

[0125] Weigh ginsenoside CK: 200 g, Rh 1 : 200 g or CK:Rh 1 =1:1, put 200 g in a 50 L round bottom flask, add 20 L of absolute ethanol, and stir until completely dissolved. Add 600 g of medicinal oral grade soybean lecithin, stir until completely dissolved. Raise the temperature to 40°C, reflux and stir for 2 hours, and evaporate to dry ethanol to obtain ginsenoside CK-phospholipid complex, Rh 1 - Phospholipid complex or CK:Rh 1 =1:1-phospholipid complex.

[0126] Weigh 100 g of ginsenoside CK-phospholipid complex and Rh 1 - Phospholipid complex 100 g or CK:Rh 1 =1:1-phospholipid complex 100 g, microcrystalline cellulose 150 g, hydroxypropyl cellulose 16 g, cross-linked povidone 16 g through a 50-mesh sieve and mix well, then add 0.5 g Tween 80 for binding The agent was granulated through a 20-mesh sieve, dried at 55°C for 3 hours, then granulated through a 18-mesh sieve, adde...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of ginsenoside CK and Rh1 and a composition thereof in preparation of medicine for improving non-alcoholic fatty hepatic fibrosis and insulin resistance, and relates to a medical application of the ginsenoside CK and Rh1 and the composition thereof. According to the application, in-vitro and in-vivo studies show that the ginsenoside CK and Rh1 and the composition thereof can regulate and control synthesis and degradation of epimatrix of hepatic stellate cells (HSC-T6) of mice, significantly improve the abnormal liver function, lipid metabolism disorders, abnormal glucose metabolism and hepatic fibrosis degree of the non-alcoholic fatty hepatic fibrosis mice, and has a development prospect for serving as the medicine of combination of non-alcoholic fatty hepatic fibrosis and insulin resistance.

Description

technical field [0001] The invention belongs to pharmaceutical products, in particular to ginsenoside CK, Rh 1 The medical use of its composition. Background technique [0002] NAFLF (Non-Alcoholic Fatty Liver Fibrosis, non-alcoholic fatty liver fibrosis) and NASH (Non-Alcoholic Steato-Hepatitis, non-alcoholic steatohepatitis) are NAFLD (nonalcoholic fatty liver disease, non-alcoholic fatty liver disease) Different pathological stages in the disease spectrum. NAFLF, NASH are closely related to insulin resistance. As a chronic liver disease, NAFLD affects more than 10 million people worldwide, and about 30% of NAFLD patients will progress to NASH, NAFLF, liver cirrhosis, or hepatocellular carcinoma. Due to the rising incidence of obesity and NAFLD, the number of NAFLF patients will more than triple in the next 10 to 15 years. [0003] The essence of NAFLF is the excessive deposition of ECM due to the imbalance between synthesis and degradation of extracellular matrix (EC...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/704A61P1/16A61P5/50
Inventor 马岚青文孟良邹成钢陈徐佳朱云珍艾黎缪应雷董向前梁红杨胜江武绍梅黄开心李铭刚赵江源
Owner KUNMING NOVOGINSENG BIOENG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap